Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Ischl – page 7

307 clinical trials in Bad Ischl, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Ischl at a glance
307
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

307 trials in Bad Ischl

Open in trial search

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Fabry's disease

Recruiting

Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Pegunigalsidase Alfa
  • Sponsor:Chiesi Farmaceutici S.p.A.

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Malabsorption

Recruiting

Study on the Safety of ELGN-2112 for Preterm Infants with Intestinal Malabsorption

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Insulin Human
  • Sponsor:Elgan Pharma Ltd.

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Neoplasm

Recruiting

Study of Zenocutuzumab for Patients with Solid Tumors with NRG1 Fusion

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zenocutuzumab
  • Sponsor:Partner Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Ischl

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focused on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through combination therapy approaches. Studies explore the effectiveness of triple therapy combinations including bronchodilators and anti-inflammatory medications.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Treatment Optimization

Clinical investigations aim to improve patient outcomes in moderate to severe COPD cases.

02 Pulmonary Therapeutics

Advanced research examining the efficacy of benralizumab in treating patients with moderate to very severe COPD. Focus on reducing exacerbation frequency in patients with elevated blood eosinophils.

  • Exacerbation Management
  • Targeted Therapy
  • Disease Control

Studies specifically target patients with a history of frequent COPD exacerbations.

03 Respiratory Care Innovation

Development of new therapeutic approaches using metered-dose inhalers for COPD management. Research combines multiple active ingredients to achieve optimal bronchodilation and anti-inflammatory effects.

  • Medication Delivery Systems
  • Combination Therapies
  • Treatment Efficacy

Emphasis on improving delivery methods and treatment effectiveness for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.